Cencora raised its full-year adjusted EPS outlook and announced a US$1b buyback after a stronger fiscal third quarter, and said it plans to brief investors at two New York healthcare conferences. The upbeat earnings message has not lifted the shares in the near term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78, while the 90 day share price return stands at 13.82%, the 1 year total shareholder return at 7.28% and the 5 year total shareholder return at 165.36%. The most followed narrative values Cencora at a fair value of $372.58, above the recent $308.78 close and below the $369.31 analyst price target, built on a 7.24% discount rate and assumptions of revenue rising to $394.5b and earnings reaching $3.4b by 2029, with the shares trading on a 24.3x P/E at that point. That narrative also weighs the added debt from OneOncology alongside recent acquisitions such as Retina Consultants of America, and warns the story could change quickly if lower fee biosimilars keep squeezing margins or if international logistics weakness drags on group profitability longer than analysts expect.
Cencora Inc.Cencora raised its full-year adjusted EPS outlook and announced a US$1b buyback after a stronger fiscal third quarter.
